ライフサイエンスコーパス: prosthesis

1 d the design of a replacement subtalar joint prosthesis.

2 ps, stroke than did recipients of a biologic prosthesis.

3 fy their behavior to more fully embody their prosthesis.

4 nee prostheses, and 1 patient with a femoral prosthesis.

5 he mechanical stimulation of a bone-anchored prosthesis.

6 thesis than among recipients of a mechanical prosthesis.

7 ients with a malfunctioning cobalt-alloy hip prosthesis.

8 ter implantation of this new artificial iris prosthesis.

9 ring valvuloplasty, and repositioning of the prosthesis.

10 ver been described in a patient with an iris prosthesis.

11 ve endophthalmitis in a patient with an iris prosthesis.

12 f 36) in subjects with an antimicrobial-free prosthesis.

13 ng the progressive opening of the esophageal prosthesis.

14 y from 13 mechanical sensors embedded on the prosthesis.

15 lacement and loss of retention of his ocular prosthesis.

16 dical Products Inc, California, USA) retinal prosthesis.

17 a random, scattered signal presented to the prosthesis.

18 ng movements from ECoG to control a grasping prosthesis.

19 amputation improved control of a robotic leg prosthesis.

20 traction and the placement of the definitive prosthesis.

21 a tooth or an implant supported fixed dental prosthesis.

22 ared-light-sensitive photovoltaic subretinal prosthesis.

23 stiffness using a custom variable-stiffness prosthesis.

24 ivate movement and sensory feedback from the prosthesis.

25 turation following the delivery of the final prosthesis.

26 patients implanted with the Argus II Retinal Prosthesis.

27 outcomes of surgical explantation of a TAVR prosthesis.

28 to non-amputees compared to using a passive prosthesis.

29 rst 100 patients who underwent TMVR with the prosthesis.

30 re MAC using an anatomically designed mitral prosthesis.

31 nalyzed totaling 406 patients (Suture = 186, Prosthesis = 220).

32 actures (4 patients, 2.5%), loosening of the prosthesis (3 patients, 1.9%), joint dislocation (2 pati

33 ore frequently involved the aortic valve and prosthesis (64.3% vs. 46.7%; p < 0.001; and 35.9% vs. 28

34 ck of elongation effect or shortening of the prosthesis (7 patients, 4.5%), prosthesis fractures (4 p

35 imultaneously optimizing human movements and prosthesis actuation, minimizing a weighted sum of human

36 The extent to which the prosthesis affected the body schema, the representation

37 ther, in animals that had learned to use the prosthesis, altering the topographic mapping from IR sen

38 For uncemented prosthesis, alternative antimicrobial approaches are nec

39 igher mortality than receipt of a mechanical prosthesis among patients 40 to 49 years of age (44.1% v

40 -year mortality than receipt of a mechanical prosthesis among patients 45 to 54 years of age (30.6% v

41 reas MRI metal artifacts may preclude direct prosthesis analysis, MRI provided information on PHV-rel

42 d IE (188 prosthetic valves/ascending aortic prosthesis and 115 native valves) were studied.

43 ir mandibular ramus was elongated by the TMJ prosthesis and 2 patients were combined with Le Fort I o

44 bjects with an antimicrobial-loaded cemented prosthesis and 58.3% (21 of 36) in subjects with an anti

45 view recent advances in optogenetics, visual prosthesis and electrostimulation to treat outer retinal

46 h as repositioning or retrieval of the valve prosthesis and embolization of the prosthesis; and other

47 noparticles, e.g. in drug delivery, advanced prosthesis and surgical implants.

48 temporal patterns of retinal activity with a prosthesis and that temporal multiplexing may aid in rep

49 tion in response to interactions between the prosthesis and the environment.

50 especially the interaction between the valve prosthesis and the native aortic valve, may play a major

51 ent, standardized, reproducible exenteration prosthesis and to overcome the principal barriers to an

52 al delivery of a self-expanding mitral valve prosthesis and were examined in a prospective registry f

53 e PET/CT scan, location and size/type of the prosthesis, and location and extent of the disease.

54 presence of periodontitis, smoking, type of prosthesis, and location of implants and peri-implant mu

55 LNJSA, age, intra-articular nonarthroplasty prosthesis, and number of surgical procedures.

56 ects, smoking, caries, utilizing a removable prosthesis, and plaque index.

57 struction occurred due to malrotation of the prosthesis, and successful alcohol septal ablation was p

58 n certain patients with the Argus II Retinal Prosthesis, and the direction and magnitude of this effe

59 the valve prosthesis and embolization of the prosthesis; and other complications.

60 I implant is the first-generation epiretinal prosthesis approved for an investigational clinical tria

61 The custom-made, flexible silicone iris prosthesis ArtificialIris (HumanOptics, Erlangen, German

62 pigmentosa were implanted with the Argus II prosthesis as part of a phase 1/2 feasibility study at m

63 Prosthesis embodiment, the perception of a prosthesis as part of one's body, may be an important co

64 for non-antibiotic antimicrobial uncemented prosthesis as these devices present numerous benefits, p

65 enefit that was associated with a mechanical prosthesis, as compared with a biologic prosthesis, pers

66 o guide bony mass removal and locate the TMJ prosthesis (Biomet, USA).

67 , the choice of biological versus mechanical prosthesis, bridging therapies, role of aspirin, use of

68 ting in order to improve the fixation of the prosthesis by forming a bony connection to the remainder

69 Operant control of a prosthesis by neuronal cortical activity is one of the s

70 he multifunctional control of a transhumeral prosthesis by patients who have undergone targeted muscl

71 imulations of an amputee using an ankle-foot prosthesis by simultaneously optimizing human movements

72 n of the false lumen distal to the ascending prosthesis can be a challenge both for the surgeon and t

73 antation for dysfunctional biological mitral prosthesis can be performed with minimal operative morbi

74 king with an appropriately optimized robotic prosthesis can have a lower metabolic cost--even lower t

75 The implantation of an artificial iris prosthesis can lead to a residual iris retraction syndro

76 s, indicating the emergence of a dissociated prosthesis categorisation.

77 sis usage correlated positively with greater prosthesis categorisation.

78 ional results following implantation of iris prosthesis combined with cataract surgery in eyes with p

79 mes 5 years after TAVR with a self-expanding prosthesis compared to SAVR.

80 -effectiveness of TAVR with a self-expanding prosthesis compared with surgical aortic valve replaceme

81 ization for heart failure symptoms and valve prosthesis complication; or (3) stroke.

82 vel approach of motor neuron interfacing for prosthesis control and provide new insights into the rol

83 is a nerve transfer procedure developed for prosthesis control, incidentally found to improve postam

84 signing physiologically inspired methods for prosthesis control.

85 s additional recording sites for myoelectric prosthesis control.

86 mizing a weighted sum of human metabolic and prosthesis costs.

87 ine interface (BMI) that controls a grasping prosthesis could be realized by detecting the time of gr

88 diction of appropriate projection angles for prosthesis deployment.

89 ol, our findings offer new opportunities for prosthesis design by lifting restrictions imposed by the

90 ment are connected, regardless of the actual prosthesis design.

91 ults did not show differences across the two prosthesis designs.

92 r implant (CI) is the most successful neural prosthesis developed to date.

93 arger aortic annulus (P=0.0004), and smaller prosthesis diameter (P=0.0001).

94 Finally, in situ, prosthesis diameter and ellipticity followed the same pa

95 Aortic annulus and prosthesis diameter were not predictors of postprocedura

96 microelectrodes in cerebral cortex, a neural prosthesis discriminated action potentials (spikes) in p

97 d wearing of the ocularist-made exenteration prosthesis due to altered fit, discoloration, or materia

98 Prosthesis durability remains the main concern in noneld

99 atory testing could add value in quantifying prosthesis dysfunction and could suggest a pathophysiolo

100 ng was noted in 6 of 24 patients with aortic prosthesis dysfunction and in 5 of 19 patients with mitr

101 timers are associated with aortic and mitral prosthesis dysfunction, with occasional gastrointestinal

102 olism and may identify a reversible cause of prosthesis dysfunction.

103 e, the recontoured second copy with improved prosthesis edge-to-skin interface was made without the p

104 Prosthesis embodiment, the perception of a prosthesis as

105 o hands, challenging current views of visual prosthesis embodiment.

106 to optimal solutions predict that increasing prosthesis energy cost, decreasing prosthesis mass, and

107 provides compelling evidence that the neural prosthesis enhanced functional connectivity between the

108 The use of an electronic retinal prosthesis facilitates reach-and-grasp performance.

109 eolysis and the loss of fixation in a murine prosthesis failure model.

110 regurgitation and transcatheter aortic valve prosthesis failure seems to be safe, and it is associate

111 ween TAVR and SAVR until transcatheter valve prosthesis failure time was 70% shorter than that of sur

112 low produced good symmetry, color match, and prosthesis fit.

113 However, early placement of a penile prosthesis following radical prostatectomy is now a prov

114 nt dislocation (2 patients, 1.3%), stump and prosthesis fracture (1 patient, 0.6%) and local recurren

115 tening of the prosthesis (7 patients, 4.5%), prosthesis fractures (4 patients, 2.5%), crural fracture

116 major bleeding was higher in the mechanical prosthesis group (13.0% [95% CI, 9.9%-16.1%] vs 6.6% [95

117 2.1% (95% CI, 58.2%-66.0%) in the mechanical prosthesis group (hazard ratio, 0.97 [95% CI, 0.83-1.14]

118 8.6% (95% CI, 6.2%-11.0%) in the mechanical prosthesis group (hazard ratio, 1.04 [95% CI, 0.75-1.43)

119 e of reoperation was lower in the mechanical prosthesis group compared with the bioprosthesis group.

120 ard ratio, 4.0 [1.5-11]), implantation of >1 prosthesis (hazard ratio, 5.2 [1.5-18]), and any vascula

121 the limitations of currently available valve prosthesis, heart valve tissue engineering has emerged a

122 hin their home and community using a passive prosthesis (ie, one that does not provide external power

123 Other variables, such as type of prosthesis, implant surface, and timing of prosthetic lo

124 ic valve replacement (AVR) allows for larger prosthesis implantation and may be an important adjunct

125 n the context of traumatic aniridia and iris prosthesis implantation due to other potential etiologie

126 with retinitis pigmentosa undergoing retinal prosthesis implantation.

127 and older continued to receive a mechanical prosthesis in 2011.

128 implantation of a novel magnetic oculomotor prosthesis in a patient.

129 ve replacement with a mechanical or biologic prosthesis in California in the period from 1996 through

130 alIris seems to be a safe and effective iris prosthesis in combination with an IOL having functionall

131 lvular replacement surgery and the choice of prosthesis in dialysis patients with bacterial endocardi

132 e the way for the clinical evaluation of the prosthesis in patients affected by dry atrophic age-rela

133 allow safe placement of a three-piece penile prosthesis in patients with a history of pelvic surgery.

134 gical TV replacement with a biological valve prosthesis in patients with congenital heart disease.

135 er of successful grasps was greater with the prosthesis in the 'On' setting (visit 1: median [interqu

136 ck up a high-contrast cuboid object with the prosthesis in the 'On', 'Off' or 'Scrambled' setting pre

137 Implanting a retinal prosthesis in the central macula in AMD patients [3, 4]

138 ic valve endocarditis (PVE)/ascending aortic prosthesis infection (AAPI).

139 ematics, here, we explicitly model the human-prosthesis interaction to produce a prediction of the us

140 The mean prosthesis intercommissural distance, ratio was 1.03+/-0

141 to the unintended implantation of a revision prosthesis into an infected surgical site with the risk

142 This neuromusculoskeletal prosthesis is a novel concept of artificial limb replace

143 TMJ reconstruction with standard alloplastic prosthesis is a reliable treatment for ankylosis, especi

144 tcomes in patients with the Argus II Retinal Prosthesis is dependent on a multitude of factors includ

145 Movement of the myoelectric prosthesis is enabled via decoded electromyography activ

146 itral annular calcification with a dedicated prosthesis is feasible and can result in MR relief with

147 the best available studies to determine what prosthesis is most appropriate when valve replacement is

148 replacement, either a mechanical or biologic prosthesis is used.

149 n preoperatively distinguish between aseptic prosthesis loosening and low-grade joint infection, and

150 approach in differentiating between aseptic prosthesis loosening and low-grade joint infection.

151 There was no prosthesis loosening, breakage, or infection leading to

152 is [bio-CVG], n = 180; CVG with a mechanical prosthesis [m-CVG], n = 183).

153 ncreasing prosthesis energy cost, decreasing prosthesis mass, and allowing asymmetric gaits all decre

154 of retinal neurons with an advanced retinal prosthesis may eventually provide high-resolution artifi

155 wered prosthesis) responds to changes in the prosthesis mechanics and gravitational load.

156 heter implanted self-expandable aortic valve prosthesis (Medtronic CoreValve).

157 3 patients underwent TAVI with the CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) at 14 cen

158 radient, larger valve area, and less patient-prosthesis mismatch (all P<0.001), but more paravalvular

159 NSVD) was defined as moderate/severe patient-prosthesis mismatch at 3 months or moderate/severe parav

160 in small surgical valves because of patient/prosthesis mismatch.

161 nt aortic valve replacement with a Mitroflow prosthesis (models 12A/LX) between 2002 and 2007.

162 esis, prosthesis users represented their own prosthesis more dissimilarly to hands, challenging curre

163 n = 3) osteomyelitis (n = 2), infected joint prosthesis (n = 2), and peritonitis (n = 2) being the mo

164 radiographs of patients with an aortic valve prosthesis (n = 473) were analyzed to determine the loca

165 ot (n=78) or a mechanically valved composite prosthesis (n=127) between February 1998 and July 2011.

166 1 to TAVR using the self-expanding CoreValve prosthesis (n=145) or SAVR using any stented bio-prosthe

167 dental implants, who had neither a metallic prosthesis nor metal restorations in neighboring teeth.

168 pment of a neurotransmitter-based subretinal prosthesis offering more naturalistic vision and better

169 sfully treated, two cases by exchange of the prosthesis, one with debridement and retention, and one

170 .6 [95% confidence interval {CI}, 1.5-4.4]), prosthesis (OR, 1.9 [95% CI, 1.1-3.5]), Staphylococcus a

171 onfidence interval, 3.23-36.91; P<0.001) and prosthesis oversizing >/=20% (odds ratio, 8.38; 95% conf

172 the S3-THV, despite reduced annulus area to prosthesis oversizing (8.2+/-5.1 versus 18.2+/-10.7%, P=

173 ment was quantified using a survey regarding prosthesis ownership and agency.

174 replacement had a lower incidence of severe prosthesis-patient mismatch (19.7% versus 37.5%; P=0.03)

175 2)/m(2); P=0.003), and lower rates of severe prosthesis-patient mismatch (3% versus 22%; P=0.004).

176 longer cardiopulmonary bypass duration, and prosthesis-patient mismatch (indexed effective orifice a

177 Furthermore, prosthesis-patient mismatch (PPM) after aortic valve rep

178 Little is known about the incidence of prosthesis-patient mismatch (PPM) and its impact on outc

179 The prevalence of prosthesis-patient mismatch (PPM) and its impact on surv

180 s with a different propensity for developing prosthesis-patient mismatch (PPM), considering annulus s

181 nging because they are at increased risk for prosthesis-patient mismatch and impaired outcomes.

182 The percentage of severe prosthesis-patient mismatch at 30 days was low and simil

183 le, there were no differences in the rate of prosthesis-patient mismatch between groups, and a signif

184 access cohort, there were no differences in prosthesis-patient mismatch between the small aortic ann

185 ransvalvular gradients and consequently less prosthesis-patient mismatch compared with the SAPIEN 3 i

186 Severe prosthesis-patient mismatch was defined as an effective

187 Preexisting severe prosthesis-patient mismatch was not associated with 3-ye

188 Preexisting surgical valve prosthesis-patient mismatch was not associated with mort

189 Preexisting surgical valve prosthesis-patient mismatch was present in 47.2% of the

190 orse outcome at 1 year whereas AR and severe prosthesis-patient mismatch were not.

191 gradients, valve areas, percentage of severe prosthesis-patient mismatch, and left ventricular mass r

192 TAVR patients had higher indexed EOA, lower prosthesis-patient mismatch, and more aortic regurgitati

193 Incomplete LV recovery, prosthesis-patient mismatch, low transaortic valve press

194 ion, but not moderate to severe AR or severe prosthesis-patient mismatch, were associated with increa

195 ed by presence of preexisting surgical valve prosthesis-patient mismatch.

196 rehabilitation approaches to augment retinal prosthesis performance.

197 ical prosthesis, as compared with a biologic prosthesis, persisted until 70 years of age among patien

198 Penile prosthesis placement results in early return to sexual f

199 melanoma, combined cataract surgery and iris prosthesis placement, with or without iris reconstructio

200 with BPVT were matched 1:2 for age, sex, and prosthesis position with patients whose valves were expl

201 ed retrospectively from the Argus II Retinal Prosthesis Post-Approval study.

202 tanium-encased, rare-earth magnet oculomotor prosthesis, powered to damp nystagmus without interferin

203 ontrols' representation of a similar looking prosthesis, prosthesis users represented their own prost

204 trial population, TAVR with a self-expanding prosthesis provided meaningful clinical benefits compare

205 Increased prosthesis push-off significantly reduced metabolic ener

206 imental test of this idea wherein ankle-foot prosthesis push-off work was incrementally varied in iso

207 rence in the rate of cardiovascular death or prosthesis reintervention was found.

208 Subjects with frequent prosthesis removal had a significantly (P = .02) greater

209 relapse, death, need for salvage therapy, or prosthesis removal occurred.

210 e found in subjects with higher frequency of prosthesis removal.

211 function and in 5 of 19 patients with mitral prosthesis/repair dysfunction and was associated with a

212 A dexterous prosthesis requires the acquisition of control signals t

213 ed how each system (i.e. amputee and powered prosthesis) responds to changes in the prosthesis mechan

214 r implant (CI) is the most successful neural prosthesis, restoring the sensation of sound in people w

215 there is no association between the type of prosthesis retention and peri-implant diseases.

216 e, reoperation, or complications, as well as prosthesis retention in anophthalmic socket cases.

217 tions, using a carbon fibre running-specific prosthesis (RSP).

218 onically implanted with the Argus II retinal prosthesis (Second Sight Medical Products, Inc., Sylmar,

219 omes in left-sided endocarditis based on the prosthesis selected for implantation are limited and no

220 These results emphasize the need of careful prosthesis selection in each individual patient.

221 Valve procedure and valve prosthesis selection when replacement is indicated can p

222 brain injury can be facilitated by a neural prosthesis serving as a communication link between dista

223 lications in future mind-controlled auditory prosthesis.SIGNIFICANCE STATEMENT Speech is a highly com

224 in-computer interface system using an online prosthesis simulator, a simple human-in-the-loop pyschop

225 : 1.46; 95% CI: 1.03 to 2.08; p = 0.034) and prosthesis size <=23 mm (aOR: 3.43; 95% CI: 2.41 to 4.89

226 Mean prosthesis size implanted was slightly smaller in patien

227 ( P<0.001), while there was no difference in prosthesis size in patients who underwent SAVR ( P=0.74)

228 of paravalvular regurgitation, compared with prosthesis sizing with two-dimensional echocardiography.

229 Patient selection, prosthesis sizing, and access strategies heavily rely on

230 supporting appropriate patient selection and prosthesis sizing.

231 operative cultures were negative, but PCR of prosthesis sonicate fluid was positive, as was stool cul

232 Digital construction of the anterior prosthesis surface was based on the mirrored image of th

233 Marginal bone loss (BL) and implant and prosthesis survival rates were calculated.

234 MainOutcomeMeasures: Prosthesis symmetry, skin tone match, comfort of wear, a

235 ost-effectiveness of the Argus(R) II Retinal Prosthesis System (Argus II) in Retinitis Pigmentosa (RP

236 ortions by asking users of the Argus retinal prosthesis system (Second Sight Medical Products Inc.) t

237 The Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, S

238 ability, and benefit of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, S

239 s on the development of the Argus II retinal prosthesis system (Second Sight Medical Products, Inc.,

240 Products Inc. developed Argus II, a retinal prosthesis system for treating RP.

241 e collective experiences of Argus II Retinal Prosthesis System investigators to review strategies to

242 flatscreen monitor in 3 conditions: with the prosthesis system on and a 1-to-1 mapping of spatial inf

243 orm the task significantly better with their prosthesis system than they were with their residual vis

244 After the Argus II Retinal Prosthesis System was implanted, complications and anato

245 Implantation of the Argus II Retinal Prosthesis System was safely performed in all patients.

246 cantly higher among recipients of a biologic prosthesis than among recipients of a mechanical prosthe

247 he Shore 40 silicone elastomer to generate a prosthesis that approximates the patient's skin tone.

248 r implants are the first example of a neural prosthesis that can substitute a sensory organ: they byp

249 d test a target-based cortical-spinal neural prosthesis that employs neural activity recorded from pr

250 entation of an integrated robotic knee-ankle prosthesis that facilitates the real-world testing of it

251 siderable evidence that a semicircular canal prosthesis that senses angular head velocity and stimula

252 rosthesis users' representation of their own prosthesis to controls' representation of a similar look

253 ted to artificial sensors in the digits of a prosthesis to generate sensory feedback, which was then

254 e regarding the potential utility of a canal prosthesis to improve perceptual deficits.

255 m and combined with data from sensors on the prosthesis to interpret the patient's intended movements

256 rding to age, sex, year of implantation, and prosthesis type and position.

257 he intact side of the body was unaffected by prosthesis type.

258 Prosthesis underexpansion is constantly observed in BAV.

259 Greater daily life prosthesis usage correlated positively with greater pros

260 mbodiment is a direct consequence of regular prosthesis use would offer insight on how individuals wi

261 promises to improve assessment of real world prosthesis use, leading to a better matching of prosthes

262 nd arguably also the prior experience of the prosthesis user.

263 e artificial somatosensory percepts by human prosthesis users has not been studied.

264 resentation of a similar looking prosthesis, prosthesis users represented their own prosthesis more d

265 whether neural embodiment actually occurs in prosthesis users' occipitotemporal cortex (OTC).

266 Moreover, when comparing prosthesis users' representation of their own prosthesis

267 oved environment perception of bone-anchored prosthesis users.

268 differs between body-powered and myoelectric prosthesis users.

269 The first copy of every 3D-printed orbital prosthesis using this fabrication workflow produced good

270 A visual cortical prosthesis (VCP) has long been proposed as a strategy fo

271 often report a social stigma associated with prosthesis visibility.

272 y showed that culture of samples obtained by prosthesis vortexing and sonication was more sensitive t

273 The overall retention rate of the initial prosthesis was 77%.

274 tic-valve replacement, receipt of a biologic prosthesis was associated with significantly higher 15-y

275 ral-valve replacement, receipt of a biologic prosthesis was associated with significantly higher mort

276 silicone casting for fabrication of orbital prosthesis was developed and validated.

277 However, using either a passive or active prosthesis was different compared to non-amputees in tru

278 Early hemodynamic performance of the prosthesis was excellent.

279 r more than 2 post-operative years, the iris prosthesis was explanted, and intravitreal cultures show

280 which is the largest experience to date, the prosthesis was highly effective in relieving MR and impr

281 In all patients, the prosthesis was implanted successfully under the macula,

282 Type of prosthesis was unrelated to mortality.

283 These results indicate that regular prosthesis wear and embodiment are connected, regardless

284 (acquired or congenital) and hours of daily prosthesis wear.

285 were 50 subjects (mean age: 31.3 years, mean prosthesis wear: 96.1 months).

286 subjects implanted with the Argus II retinal prosthesis were able to perform a motion detection task

287 n TAVR registry with CoreValve and Sapien-XT prosthesis were compared according to the implantation t

288 ts with implantation of the Argus II Retinal Prosthesis were enrolled in this single-institution retr

289 utions to H at toe-off when using the active prosthesis were more similar to non-amputees compared to

290 mmunity-acquired cholangitis without biliary prosthesis who do not need intensive care, piperacillin/

291 lateral trans-tibial amputees who utilized a prosthesis with a PTB feature and 15 age- and sex- match

292 Our results suggest that the use of a prosthesis with a PTB feature contributes to morphologic

293 atients who underwent TAVR received a larger prosthesis with increasing indexed annulus size ( P<0.00

294 (i.e. weighted backpack) and a powered knee prosthesis with two pre-programmed controller settings (

295 ith biological and two with mechanical valve prosthesis) with available post-treatment cardiac magnet

296 (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement.

297 jects (>/=6 years and >/=6 months of wearing prosthesis) with unilateral acquired anophthalmic socket

298 We show that multipixel stimulation of the prosthesis within radiation safety limits enabled eye tr

299 expenditure, with a 14% reduction at maximum prosthesis work.

300 e principal barriers to an affordable custom prosthesis worldwide: access and cost.